Arcutis Biotherapeutics, Inc. officer Todd Watanabe sells $139,466 of ARQT stock
The officer sold at an average of $31.86 a share, according to a Form 4 filed with the SEC on Nov 4. Information only, not investment advice.
An officer at Arcutis Biotherapeutics, Inc., Todd Watanabe, sold 4,377 shares of the company's stock on the open market on Nov 2. The sale, at an average of $31.86 a share, comes to $139,466.
The filing does not mark the sale as made under a Rule 10b5-1 trading plan. The trade was reported within two business days, as Section 16 requires.
After the trade, the filing lists 712,826 shares held.
Figures come from the Form 4 filed with the SEC; the table lists the open-market rows this article covers.
| Company | Arcutis Biotherapeutics, Inc. (ARQT) |
|---|---|
| Insider | Todd Watanabe |
| Role | Officer |
| Transaction | Open-market sale (code S) |
| Shares | 4,377 |
| Average price | $31.86 |
| Value | $139,466 |
| Trade date | Nov 2, 2026 |
| Filed with the SEC | Nov 4, 2026, 6:38 PM ET |
| Shares held after | 712,826 |
| Ownership | Direct |
| Rule 10b5-1 plan | Not marked in the filing |
Open the full breakdown of this ARQT trade
See earlier insider stories on Arcutis Biotherapeutics, Inc. · See more large insider sales
Source: SEC Form 4. Information only, not investment advice. Not affiliated with or endorsed by the U.S. Securities and Exchange Commission.
Related Articles
- Insider Trading News
Adaptive Biotechnologies president and COO Julie Rubinstein sells $897k shares
- Insider Trading News
Cluster sell at Assembly Biosciences, Inc.: four insiders sell $237,648 of ASMB
- Insider Trading News
Christine Ring, a chief legal officer at Nurix Therapeutics, Inc., sells $103,986 of stock
- Insider Trading News
RA Capital Management, L.P., a director at Bambusa Therapeutics, Inc., buys $46.6M of stock
- Insider Trading News
Ligand Pharmaceuticals Inc insider Jason Aryeh sells $676,158 in LGND shares